Clinical Trial Update: A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating lasmiditan (LY573144) for a single migraine attack in Japanese participants with migraine has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 2 | Status: COMPLETED | Results posted: 2021-05-05